BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD
BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal…
The $2 Trillion Valuation Debate Skips What Anthropic Knows
Pharmacore secures funding to improve medication regimen reviews in long-term care